Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR)
Sponsor: Eye & ENT Hospital of Fudan University
Listed as NCT03452657, this PHASE3 trial focuses on Diabetic Retinopathy and Ranibizumab and remains ongoing. Sponsored by Eye & ENT Hospital of Fudan University, it has been updated 7 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Sep 2020 — Jan 2021 [monthly]
Unknown Status PHASE3
-
Jul 2020 — Sep 2020 [monthly]
Unknown Status PHASE3
Status: Not Yet Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jun 2018 — Jul 2020 [monthly]
Not Yet Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Eye & ENT Hospital of Fudan University
- RenJi Hospital
- Shanghai 10th People's Hospital
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Shanghai Jiao Tong University Affiliated Sixth People's Hospital
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- Shanghai Tongji Hospital, Tongji University School of Medicine
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .